Jakobi, K.; Beyer, S.; Koch, A.; Thomas, D.; Schwalm, S.; Zeuzem, S.; Pfeilschifter, J.; Grammatikos, G.
Sorafenib Treatment and Modulation of the Sphingolipid Pathway Affect Proliferation and Viability of Hepatocellular Carcinoma In Vitro. Int. J. Mol. Sci. 2020, 21, 2409.
https://doi.org/10.3390/ijms21072409
AMA Style
Jakobi K, Beyer S, Koch A, Thomas D, Schwalm S, Zeuzem S, Pfeilschifter J, Grammatikos G.
Sorafenib Treatment and Modulation of the Sphingolipid Pathway Affect Proliferation and Viability of Hepatocellular Carcinoma In Vitro. International Journal of Molecular Sciences. 2020; 21(7):2409.
https://doi.org/10.3390/ijms21072409
Chicago/Turabian Style
Jakobi, Katja, Sandra Beyer, Alexander Koch, Dominique Thomas, Stephanie Schwalm, Stefan Zeuzem, Josef Pfeilschifter, and Georgios Grammatikos.
2020. "Sorafenib Treatment and Modulation of the Sphingolipid Pathway Affect Proliferation and Viability of Hepatocellular Carcinoma In Vitro" International Journal of Molecular Sciences 21, no. 7: 2409.
https://doi.org/10.3390/ijms21072409
APA Style
Jakobi, K., Beyer, S., Koch, A., Thomas, D., Schwalm, S., Zeuzem, S., Pfeilschifter, J., & Grammatikos, G.
(2020). Sorafenib Treatment and Modulation of the Sphingolipid Pathway Affect Proliferation and Viability of Hepatocellular Carcinoma In Vitro. International Journal of Molecular Sciences, 21(7), 2409.
https://doi.org/10.3390/ijms21072409